Abarceo AB has developed new voltage-dependent anion-selective channel protein 1 (VDAC1) inhibitors reported to be useful for the treatment of diabetes type 1 and 2.
Stimulating the production of β cells in the pancreas of individuals with type 1 diabetes may be a way to renormalize their glucose metabolism. Researchers from Spain and the U.S. may have moved one step closer to this goal by stimulating formation of new β cells in the pancreas of a mouse model of diabetes using the cyclic peptide THR-123, which binds and activates the receptor for bone morphogenetic protein (BMP).
Incretin-based therapies have demonstrated substantial efficacy in the treatment of metabolic diseases such as obesity and type 2 diabetes but the need for frequent injections remains a major barrier to patient adherence and comfort.
Palatin Technologies Inc. has announced preclinical results for PL-7737, an oral selective melanocortin MC4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity.
Launched out of 5AM Ventures’ 4:59 Initiative, Renasant Bio Inc. has secured $54.5 million in seed funding to support development of treatments for autosomal dominant polycystic kidney disease (ADPKD), a genetic disease caused by mutations in the PKD1 and PKD2 genes, which encode polycystin proteins PC1 and PC2 that come together to form a calcium ion channel vital for kidney function.
A glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist developed by Jiangsu Hengrui Pharmaceuticals Co. Ltd. and licensed by Kailera Therapeutics Inc. has shown a mean weight loss of 19.2% at the 6-mg dose with no plateau over 48 weeks in a phase III trial conducted in China.
Obesity and diabetes are known risk factors for sarcopenia. Insulin resistance that occurs during type 2 diabetes promotes impaired synthesis of muscle protein and muscle breakdown. Juvena Therapeutics Inc. has presented data at ENDO 2025 conference for JUV-161, a novel secreted protein that induces insulin sensitization, regarding its impact on blood glucose and muscle in mice with type 2 diabetes (db/db mice).
Acromegaly is a rare, chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), most commonly resulting from a benign pituitary adenoma.
Polycystic ovary syndrome is a common endocrine disorder in women of reproductive age and characterized by obesity, insulin resistance and renal injury.
GIPR/GLP-1R-targeting agents have demonstrated significant efficacy in appetite suppression and weight reduction; however, their adverse effect profiles and tolerability issues highlight the need for alternative or complementary therapeutic strategies in the management of obesity. Researchers from Juvena Therapeutics Inc. reported on the preclinical profile of JUV-112, discovered using Juvena’s proprietary JuvNET platform.
RSS
